Voya Investment Management LLC boosted its stake in Teligent, Inc. (NASDAQ:TLGT) by 16.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,342 shares of the company’s stock after purchasing an additional 3,234 shares during the quarter. Voya Investment Management LLC’s holdings in Teligent were worth $214,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC increased its holdings in Teligent by 85.6% in the second quarter. Parametric Portfolio Associates LLC now owns 34,549 shares of the company’s stock valued at $316,000 after purchasing an additional 15,933 shares during the last quarter. FMR LLC bought a new stake in Teligent in the second quarter valued at about $6,543,000. Vanguard Group Inc. increased its holdings in Teligent by 3.6% in the second quarter. Vanguard Group Inc. now owns 2,048,984 shares of the company’s stock valued at $18,748,000 after purchasing an additional 72,093 shares during the last quarter. Northern Trust Corp increased its holdings in Teligent by 2.3% in the second quarter. Northern Trust Corp now owns 565,682 shares of the company’s stock valued at $5,176,000 after purchasing an additional 12,758 shares during the last quarter. Finally, RK Capital Management LLC bought a new stake in Teligent in the second quarter valued at about $4,581,000. Institutional investors and hedge funds own 67.70% of the company’s stock.
TLGT has been the subject of a number of recent analyst reports. Canaccord Genuity initiated coverage on Teligent in a report on Monday, July 31st. They issued a “buy” rating and a $11.00 price objective for the company. BidaskClub downgraded Teligent from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. TheStreet downgraded Teligent from a “c-” rating to a “d+” rating in a report on Wednesday, November 1st. Zacks Investment Research upgraded Teligent from a “strong sell” rating to a “hold” rating in a report on Friday, October 13th. Finally, Deutsche Bank AG dropped their price objective on Teligent from $9.00 to $8.00 and set a “hold” rating for the company in a report on Monday, August 14th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. Teligent presently has an average rating of “Hold” and an average price target of $7.33.
ILLEGAL ACTIVITY WARNING: This news story was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://transcriptdaily.com/2017/11/20/teligent-inc-tlgt-position-raised-by-voya-investment-management-llc.html.
Teligent, Inc. (NASDAQ:TLGT) opened at $3.59 on Monday. Teligent, Inc. has a 52 week low of $2.82 and a 52 week high of $9.54. The company has a debt-to-equity ratio of 2.23, a current ratio of 3.28 and a quick ratio of 2.71.
Teligent (NASDAQ:TLGT) last posted its earnings results on Monday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.07). Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The business had revenue of $13.65 million during the quarter, compared to analyst estimates of $19.12 million. During the same period in the previous year, the firm posted $0.01 earnings per share. The firm’s revenue was down 15.5% on a year-over-year basis. equities analysts predict that Teligent, Inc. will post -0.13 EPS for the current fiscal year.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.